Barry S. Taylor

Barry S. Taylor

Auto-generated profile, based on publicly available information

Barry S. Taylor

Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2016 in Genome Biology
Verified
Journal Article
Open access
PDF file
RRRachel Rosenthal
Rachel Rosenthal
NMNicholas McGranahan
Nicholas McGranahan
JHJavier Herrero
Javier Herrero
BTBarry S. Taylor
Barry S. Taylor
CSCharles Swanton
Charles Swanton
Analysis of somatic mutations provides insight into the mutational processes that have shaped the cancer genome, but such analysis currently requires large cohorts. We develop deconstructSigs, which allows the identification of mutational signatures within a single tumor sample. Application of deconstructSigs identifies samples with DNA repair deficiencies and reveals distinct and dynamic mutational processes molding the cancer genome in esophageal adenocarcinoma compared to squamous cell carcinomas. deconstructSigs confers the ability to define mutational processes driven by environmental exposures, DNA repair abnormalities, and mutagenic processes in individual tumors with implications for precision cancer medicine.

1 September 2018 in Cancer Cell
Verified
Journal Article
Closed access
PRPedram Razavi
Pedram Razavi
MCMatthew T. Chang
Matthew T. Chang
GXGuotai Xu
Guotai Xu
CBChaitanya Bandlamudi
Chaitanya Bandlamudi
DRDara S. Ross
Dara S. Ross
JBJosé Baselga
José Baselga

30 November 2015 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
MCMatthew T Chang
Matthew T Chang
SASaurabh Asthana
Saurabh Asthana
SGSizhi Paul Gao
Sizhi Paul Gao
BLByron H Lee
Byron H Lee
JCJocelyn S Chapman
Jocelyn S Chapman
BTBarry S Taylor
Barry S Taylor
Detection of recurrently mutated nucleotides identifies novel cancer hotspots in an analysis of >11,000 human tumor samples. Mutational hotspots indicate selective pressure across a population of tumor samples, but their prevalence within and across cancer types is incompletely characterized. An approach to detect significantly mutated residues, rather than methods that identify recurrently mutated genes, may uncover new biologically and therapeutically relevant driver mutations. Here, we developed a statistical algorithm to identify recurrently mutated residues in tumor samples. We applied the algorithm to 11,119 human tumors, spanning 41 cancer types, and identified 470 somatic substitution hotspots in 275 genes. We find that half of all human tumors possess one or more mutational hotspots with widespread lineage-, position- and mutant allele–specific differences, many of which are likely functional. In total, 243 hotspots were novel and appeared to affect a broad spectrum of molecular function, including hotspots at paralogous residues of Ras-related small GTPases RAC1 and RRAS2. Redefining hotspots at mutant amino acid resolution will help elucidate the allele-specific differences in their function and could have important therapeutic implications.

2 April 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JAJoshua Armenia
Joshua Armenia
SWStephanie A. M. Wankowicz
Stephanie A. M. Wankowicz
DLDavid Liu
David Liu
JGJianjiong Gao
Jianjiong Gao
RKRitika Kundra
Ritika Kundra
EAEliezer Van Allen
Eliezer Van Allen

16 July 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CBCraig M. Bielski
Craig M. Bielski
AZAhmet Zehir
Ahmet Zehir
APAlexander V. Penson
Alexander V. Penson
MDMark T. A. Donoghue
Mark T. A. Donoghue
WCWalid Chatila
Walid Chatila
BTBarry S. Taylor
Barry S. Taylor

1 February 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MCMatthew T. Chang
Matthew T. Chang
TBTripti Shrestha Bhattarai
Tripti Shrestha Bhattarai
ASAlison M. Schram
Alison M. Schram
CBCraig M. Bielski
Craig M. Bielski
MDMark T.A. Donoghue
Mark T.A. Donoghue
BTBarry S. Taylor
Barry S. Taylor
Most mutations in cancer are rare, which complicates the identification of therapeutically significant mutations and thus limits the clinical impact of genomic profiling in patients with cancer. Here, we analyzed 24,592 cancers including 10,336 prospectively sequenced patients with advanced disease to identify mutant residues arising more frequently than expected in the absence of selection. We identified 1,165 statistically significant hotspot mutations of which 80% arose in 1 in 1,000 or fewer patients. Of 55 recurrent in-frame indels, we validated that novel AKT1 duplications induced pathway hyperactivation and conferred AKT inhibitor sensitivity. Cancer genes exhibit different rates of hotspot discovery with increasing sample size, with few approaching saturation. Consequently, 26% of all hotspots in therapeutically actionable oncogenes were novel. Upon matching a subset of affected patients directly to molecularly targeted therapy, we observed radiographic and clinical responses. Population-scale mutant allele discovery illustrates how the identification of driver mutations in cancer is far from complete. Significance: Our systematic computational, experimental, and clinical analysis of hotspot mutations in approximately 25,000 human cancers demonstrates that the long right tail of biologically and therapeutically significant mutant alleles is still incompletely characterized. Sharing prospective genomic data will accelerate hotspot identification, thereby expanding the reach of precision oncology in patients with cancer. Cancer Discov; 8(2); 174–83. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 127